By David E. Gerber, MD Posted: November 12, 2019 Dr. David E. Gerber The underlying concept for antibody–drug conjugates (ADCs) is relatively straightforward: capitalize on the highly specific targeting of monoclonal antibodies to convey a lethal payload to cancer cells while minimizing exposure of normal tissues. However, after more than 20 years of clinical development,…